stockportfolio.pro
Stocks / AUPH vs PGNY
AUPH vs PGNY
Aurinia Pharmaceuticals Inc. and Progyny, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Aurinia Pharmaceuticals Inc. (AUPH) | Progyny, Inc. (PGNY) | |
|---|---|---|
| Market cap | $2.0B | $2.0B |
| Revenue (latest FY) | $283.06M | $1.29B |
| Net income (latest FY) | $287.20M | $58.52M |
| Revenue growth (5y CAGR) | 41.4% | 30.2% |
| Net margin | 101.5% | 4.5% |
| Return on equity | 49.4% | 11.3% |
| P/E ratio | 7.3 | 33.5 |
| Dividend yield | — | — |
| Profitable years (of last 10) | 2 | 7 |
| Positive free cash flow | Yes | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open AUPH — free Open PGNY — freeFrequently asked questions
Which is bigger, AUPH or PGNY?
Aurinia Pharmaceuticals Inc. is larger by market capitalization — $2.0B versus $2.0B.
Which grows faster, AUPH or PGNY?
Over the last five fiscal years, Aurinia Pharmaceuticals Inc. grew revenue faster — 41.4%/yr versus 30.2%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.